EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management

Muhammad Ali Abid iD, Muhammad Hafi Abid iD, Abdul Haseeb Hasan iD, Muhammad Daniyal Afzal iD

Health Science Reports · 2026-07 · 9 (7)

DOI: 10.1002/hsr2.72850 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Health Science Reports, online erschienen am 20.07.2026. Verfasst von Muhammad Ali Abid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine King Edward Medical University Lahore Pakistan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Fibromyalgia (FM) is a chronic disorder characterized by widespread pain, fatigue, sleep disturbances, and cognitive issues. It is a multifactorial condition with no single definitive cause, making diagnosis challenging. Current treatments provide only limited relief, leading to significant unmet medical needs. Recently, the US FDA approved sublingual cyclobenzaprine (sCBP) for the treatment of FM, marking the first newly FDA‐approved medication for FM in over 15 years. This article aims to explore the current understanding of FM and the pharmacological properties, clinical trials, and potential benefits of sCBP in FM management, as well as the risks associated with its use and future research directions.

Methods

We searched for relevant pieces of literature addressing FM management and the development of sublingual cyclobenzaprine. Articles were selected based on their relevance to the study objectives, and the perspective presented in this manuscript was developed through the synthesis of the available evidence and findings reported in these sources.

Results

Clinical trials demonstrated that sCBP significantly reduced pain intensity in FM patients in two of the three studies (RELIEF and RESILIENT), with statistically significant mean differences in 11‐point numeric rating scale (NRS) scores compared to placebo. sCBP showed a higher peak CBP level with lower norCBP levels, supporting its enhanced pharmacokinetic profile over oral CBP. Common side effects of sCBP included oral discomfort, dry mouth, and abnormal taste, while more serious risks such as serotonin syndrome and arrhythmia were identified. Safety concerns necessitate caution when prescribing sCBP to patients with specific comorbidities or those on other serotonergic medications.

Conclusion

The approval of sCBP marks a significant advancement in the treatment of FM, addressing the limitations of current pharmacological options. As the prevalence of FM continues to rise, sCBP offers a promising therapeutic alternative, providing patients with a more effective and rapid treatment option for pain management.

Schlagwörter

Stichwörter der Autor:innen

FDA approvalcyclobenzaprinefibromyalgiasublingual cyclobenzaprine

Autor:innen und Institutionen

  • Department of Medicine King Edward Medical University Lahore Pakistan.
  • Department of Medicine Faisalabad Medical University Faisalabad Pakistan.
  • Department of Medicine Kyrgyz State Medical Academy Bishkek Kyrgyzstan.

ORCID-Profile: Muhammad Ali Abid, Muhammad Hafi Abid, Abdul Haseeb Hasan, Muhammad Daniyal Afzal

Zitieren

APA

Abid, M. A., Abid, M. H., Hasan, A. H., & Afzal, M. D. (2026). Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management. Health Science Reports, 9(7). https://doi.org/10.1002/hsr2.72850

Vancouver

Abid MA, Abid MH, Hasan AH, Afzal MD. Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management. Health Science Reports. 2026;9(7). doi:10.1002/hsr2.72850

BibTeX
@article{Abid2026,
  author = {Abid, Muhammad Ali and Abid, Muhammad Hafi and Hasan, Abdul Haseeb and Afzal, Muhammad Daniyal},
  title = {Sublingual Cyclobenzaprine Approval: Expanding Options for Fibromyalgia Management},
  journal = {Health Science Reports},
  year = {2026},
  volume = {9},
  number = {7},
  doi = {10.1002/hsr2.72850}
}
Kostenlos starten →